Apogee Therapeutics, Inc.

APGECIK 0001974640 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K filed Mar 2, 2026. Sentiment + YoY language diff vs prior year. Read sections →

Signal:Mild negative shiftFull-doc fallback

Full filing:tone -0.0139Δ-0.002188% similar+537/-600 ¶

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

May 27, 20267.01 · Regulation FD Disclosure8.01 · Other Events9.01 · Financial Statements and Exhibits May 27, 20261.01 · Entry into a Material Definitive Agreeme7.01 · Regulation FD Disclosure9.01 · Financial Statements and Exhibits May 11, 2026no items parsed Apr 24, 2026no items parsed Mar 25, 20261.01 · Entry into a Material Definitive Agreeme9.01 · Financial Statements and Exhibits

YoY shift: Lean -

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K. This filing is -0.21pp more bearish than last year's.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Apogee Therapeutics, Inc.

Name	Roles	Filings
Dambkowski Carl	Officer	27
Henderson Michael Thomas	OfficerDirector	22
Henderson Jane	Officer	15
Fairmount Funds Management LLC	Director	6
Harwin Peter Evan	Director	6

Showing 1-5 of 15

Per pagePage 1 of 3Next

Top performers

Insiders ranked by realized 90-day signed return on their open-market trades at Apogee Therapeutics, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.

#	Insider	Trades	Win rate	Avg	Median	Best	Worst
1	Dambkowski Carl	48	35%	-12.8%	-8.9%	+41.6%	-92.4%
2	Henderson Jane	16	31%	-8.7%	-11.3%	+12.8%	-27.3%
3	Fairmount Funds Management LLC	4	0%	-7.7%	-5.8%	-5.8%	-13.5%
4	Fairmount Healthcare Fund II L.P.	4	0%	-7.7%	-5.8%	-5.8%	-13.5%
5	Harwin Peter Evan	4	0%	-7.7%	-5.8%	-5.8%	-13.5%
6	Kiselak Tomas	4	0%	-7.7%	-5.8%	-5.8%	-13.5%
7	Fairmount Healthcare Co-Invest II L.P.	3	0%	-5.8%	-5.8%	-5.8%	-5.8%
8	Fairmount Healthcare Fund L.P.	3	0%	-5.8%	-5.8%	-5.8%	-5.8%
9	Henderson Michael Thomas	34	44%	-1.8%	-4.5%	+41.6%	-49.5%

All filings

88 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Apr 10, 2026	Henderson Michael Thomas Chief Executive Officer · Director	SSale	17,800	$82.48	$1,468,144
Apr 3, 2026	Henderson Jane Chief Financial Officer	SSale	1,100	$85.46	$94,006
Apr 3, 2026	Dambkowski Carl Chief Medical Officer	SSale	2,702	$85.33	$230,562
Mar 27, 2026	Henderson Jane Chief Financial Officer	SSale	2,000	$85.00	$170,000
Mar 13, 2026	Henderson Michael Thomas Chief Executive Officer · Director	SSale	8,363	$74.29	$621,287

Showing 6-10 of 88

Per pagePrevPage 2 of 18Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value